Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

Journal of clinical lipidology - 1 Jan 2000

Adiels Martin, Chapman M John, Robillard Paul, Krempf Michel, Laville Martine, Borén Jan

Abstract excerpt

BACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular risk is questioned. OBJECTIVE: To evaluate interrelationships between the effects of niacin on mixed dyslipidemia and a spectrum of metabolic and inflammatory biomarkers. METHODS: Obese, nondiabetic, hypertriglyceridemic males (n = 19) with low high-density lipoprotein-cholesterol levels received extended-release nicotinic acid for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Insulin Resistance

Share to Macrophages

Share to Metabolic Syndrome

Share to Niacin

Source

Identifiers

PMID: 29753732
DOI: 10.1016/j.jacl.2018.03.083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.PMID 29753732Read ↗

Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study.Semantic proximity Read ↗

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.Semantic proximity Read ↗

Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.Semantic proximity Read ↗

Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.Semantic proximity Read ↗

The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?Semantic proximity Read ↗

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.Semantic proximity Read ↗

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Semantic proximity Read ↗

Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients.Semantic proximity Read ↗

The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.Semantic proximity Read ↗

Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.Semantic proximity Read ↗

Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human HepatocytesSemantic proximity Read ↗

Sufficient Niacin Supply: The Missing Puzzle Piece to COVID-19, and beyond?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.